Get the Stockscreener App
2.33
2.64%
0.06
Pluri Inc stock is traded at $2.33, with a volume of 5,530.
It is up +2.64% in the last 24 hours and down -30.86% over the past month.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
See More
Previous Close:
$2.27
Open:
$2.3
24h Volume:
5,530
Relative Volume:
0.56
Market Cap:
$25.14M
Revenue:
$1.08M
Net Income/Loss:
$-26.95M
P/E Ratio:
-0.8115
EPS:
-2.8712
Net Cash Flow:
$-21.69M
1W Performance:
+0.87%
1M Performance:
-30.86%
6M Performance:
-23.36%
1Y Performance:
-47.05%
1-Day Range:
$2.30
$2.4185
1-Week Range:
$2.25
$2.5699
52-Week Range:
$2.22
$5.96
Pluri Inc Stock (PLUR) Company Profile
Name
Pluri Inc
Sector
Industry
Phone
972-74-710-7171
Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Compare PLUR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLUR
Pluri Inc
|
2.33 | 25.14M | 1.08M | -26.95M | -21.69M | -2.8712 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pluri Inc Stock (PLUR) Latest News
Pluri Inc. Q1 2026 Earnings: EPS Misses as Pre-Revenue Biotech Continues Pipeline DevelopmentReturn On Assets - newsline.com
Made Scientific, Pluristyx launch development and manufacturing partnership - ROI-NJ
Made Scientific and Pluristyx Launch Integrated iPSC Development & Manufacturing Partnership to Advance Next-Generation iPSC-derived Cell Therapies - The Malaysian Reserve
Pluri subsidiary completes U.S. cosmetic listing for two products By Investing.com - Investing.com Nigeria
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing - The Manila Times
Pluri subsidiary completes U.S. cosmetic listing for two products - Investing.com
Two new skin treatments target $90B U.S. aesthetics market - Stock Titan
Pluri's Leap from Lab to Luxury: A High-Stakes Bet on Regenerative Beauty - BriefGlance
Pluri in Good-Faith Talks on EIB Loan Resolution - TipRanks
Pluri Inc. and European Investment Bank continue loan discussions, no enforcement action expected before July - Investing.com
Pluri Biotech Ltd., Pluristem Gmbh, and Pluri Inc. Remain in Constructive Discussions with European Investment Bank Regarding EUR 20 Million Loan - marketscreener.com
Pluri (NASDAQ: PLUR) negotiates with European Investment Bank over €20M loan due 2026 - Stock Titan
Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In - Insider Monkey
7 Best Lab-Grown Meat Stocks to Invest In - Insider Monkey
Pluri Inc. (PLUR) Gains 4.6%, Approaches Resistance at $2.52Breadth Thrust - The Legal Advocate
Plurilock Security Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Plurilock Security Inc.: Plurilock Security Inc. Reports First Quarter 2026 Financial Results - FinanzNachrichten.de
Pluri Insider Ups Holding During Year - Yahoo Finance
Pluri Inc. (PLUR) Posts Modest Gain as Stock Holds Above Key SupportAdaptive Moving Average - newsline.com
Pluri Inc. Q1 2026 Earnings: EPS Misses Estimates Amid Lack of Revenue DisclosureManagement Guidance Update - The Legal Advocate
Pluri Inc. (PLUR) Climbs 3.22% as Shares Test Resistance Near $2.49Community Momentum Stocks - Newser
Pluri Inc. (PLUR) Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerRetail Trader Picks - Newser
This Pluri Insider Increased Their Holding In The Last Year - simplywall.st
Pluri: Fiscal Q3 Earnings Snapshot - marketscreener.com
Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
Pluri Inc. (NASDAQ: PLUR) faces going concern risk amid EIB debt wall - Stock Titan
Number of shareholders of Pluri Inc. – NASDAQ:PLUR - TradingView
PLURI INC (PLUR) Eps Diluted (TTM) - Zacks Investment Research
TradingKey - TradingKey
MSN Money - MSN
Pluri (PLUR) Earnings Date and Reports 2026 $PLUR - MarketBeat
MSN - MSN
PLUR Pluri reports wider than projected Q1 2026 loss while shares notch small gains in today’s trading session.Competitive Risk - newser.com
Insider-backed Chutzpah Holdings (NASDAQ: PLUR) buys 625K shares and warrants - Stock Titan
Weinstein group (PLUR) discloses 3.79M-share Pluri stake via CHL, CHLP, Plantae - Stock Titan
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC) - bioinformant.com
Is Pluri (PLUR) stock cheap today | Pluri Misses EPS Estimates by 7.1% Lagging Street ViewsShared Buy Zones - newser.com
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - Sahm
Pluri files to sell 3.425M common shares for holders - MSN
Nasdaq Interview: Pluri CEO On Its Cell Technology And Innovation In Coffee Industry (Wsy7Unggil) - fathomjournal.org
Future Of Biotech: Pluri's 3D Cell Expansion Technology & CDMO For Global Impact | Nasdaq Interview (01igB6URuM) - fathomjournal.org
Pluri (NASDAQ: PLUR) details 2026 board elections, auditor vote and Kokomodo deal - Stock Titan
Pluri (PLUR) Profitability Outlook | Pluri posts 7.1% EPS miss, wider loss vs forecastAnalyst Stock Picks - Newser
PLUR Pluri posts 309.8 percent year over year revenue growth in Q1 2026 as quarterly EPS misses analyst estimates.Shared Buy Zones - Xã Thanh Hà
Plurilock Security Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pluri Inc Stock (PLUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):